At HEMEX, we regularly organize invitation-only pitch days, where selected startups get the opportunity to pitch in front of potential investors. The focus of our last 2019 pitch session was on startups seeking to revolutionize cancer diagnosis and treatment. Thank you Christina Vallgren, Marcus Palm, Martin Stauber, Seline Eisenring, Michael Krauthammer and Peter Nestorov for […]
Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading →Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading →Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading →Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading →Diversity Hemex Team Innovation
Empowering our people, transforming our world in 2023
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading →